ABSTRACT. Defects in pyruvate dehydrogenase, the first catalytic component of the pyruvate dehydrogenase complex, are the most common cause of pyruvate dehydrogenase complex deficiency. A family with variable pyruvate dehydrogenase complex deficiency had been described in which cultured skin fibroblast s of affected family members had normal pyruvate dehydrogenase complex activity, but different tissues and blood lymphocytes had significantly diminished activities. Enzymatic activity and immunoblot studies indicated that pyruvate dehydrogenase was affected. Further evidence is presented here showing that the defect affecting pyruvate dehydrogenase complex activity is posttranscriptional. Sequencing of the coding region of the a -subunit of pyruvate dehydrogenase revealed a point mutation in the codon for amino acid 234 resulting in a substitution of glycine for arginine. Stud y of other members of the family suggested that this mutation is inherited in a sex-linked mode. The point mutation is located in a highly conserved region of the pyruvate dehydrogenase a-subunit gene that contains both hydrophobic and positively charged amino acid residues. Variable expression of pyruvate dehydrogenase complex deficiency in this case may be due to instability of the pyruvate dehydrogenase heterotetramer in specific tissues because of a disruption in subunit-subunit interaction. (Pediatr Res 32: 169-174,1992) Abbreviations Ell pyruvate dehydrogenase E1a , a -subunit of E. E 1,8 , ,8-subunit of E 1 E3, dihydrolipoamide dehydrogenase PDC, pyruvate dehydrogenase complex PCR, polymerase chain reaction Th e PDC is a nuclear-encoded mitochondrial enzyme complex t hat catalyzes the conversion of pyruvate to acetyl-CoA. PDC consists of thre e catalytic components: E 1 (pyruvate:lipoam ide 2-oxidoreductase, EC 1.2.4.1.), dihydrolipoamide acetyltransferase, and E 3 as well as a prot ein X that forms part of the comp lex. The E 1 com ponent consists of two subunits encoded by different genes, a and (3, which com bine as a heterotetramer. Regulation of the complex is via phosphorylation by Ei-kinase and dephosphorylation by phospho E j-phosphatase of th ree specific serine residues on Ela (1,2).
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PDC deficiency, an inborn error of pyruvate metabolism, is manifested by elevated serum pyruvat e and lactate. Individuals with PDC deficiency have varying levels of neur ologic dysfunction ranging from mild ataxia to neuroanatom icallesions incompatible with life (3, 4) . Most PDC mutations affect the E1 component of PDC (5, 6) . Recently, identification of mut ations affecting Ela has been facilitated by the cloning and charac terization of cDNA (7-10) and genomic DNA for Eta (1 1, 12) . By in situ hybridization, the Ela gene has been localized to the X chromosome (13) . Mutations involving deletions or single base changes have been found on the a -subunit (14) (15) (16) (17) .
Previously, we described a family with PDC deficiency in which variable PDC enzymatic activity was observed in different tissues (18) . The proband was found to have minimal PDC activity in his lymph ocytes, heart , liver, muscle, and brain, whereas cultured skin fibroblasts had norma l activity. These findings were confirmed in lympho cytes and cultur ed skin fibroblasts from a similarly affected male sibling of the prob and. Additiona l family studies suggested a sex-linked pattern of inheritance for variable expression of PDC deficiency. Enzymatic assay of the catalytic com ponents of PDC indicated that the defect only affected the E1 component. Immunoreactivity studies using antibodies to specific catalytic components demonstrated that tissues deficient in PDC activity lacked imm unoreactive material to both E I subunits, whereas cultured skin fibroblasts that had normal activity also had normal levels of immunoreactive material for E,« and E t (3. In this report, we present evidence that a point mutation located in the coding region of Ela causes PDC deficiency in this fam ily. (19) . The amount of RNA in each sample was determined by UV absorbance at 260 nm . Geno mic DNA was prepared from cultured skin fibroblasts by harvesting cells in PBS followed by boiling the cells for 2 min in a solutio n of 0. 1 M NaOH , 2 M NaCI (20) and centrifuging the cells at 16 000 x g for 10 min . Aliquots of the supernata nt containing genomic D NA were used directly for PCR experiments described below.
RNA blot analysis. Equal am ounts of total RNA from different samples were separa ted by electrophoresis in an agarose gel containing 1% formaldehyde and tran sferred to a memb rane (Genescreen; Dupont-New England Nu clear, Wilmington , DE). RNA on the membrane was hybridized (2 1) with 32P-labeled probes prepared from denatured double-stranded cDNA fragments of E,«, Ed), and E 3 (6) using the random priming method (22, 23) . After autora diography and removal of previously used radioactive probes (following the prot ocol recom mended in the manufacturer's instructions), the same membrane was rehybridized with successive cDNA probes .
Reverse transcription and DNA amplification. Oligodeoxynucleotide primers were synthesized on a 380A DNA synthesizer (Applied Biosystems, Foster, CA). Th e seq uence and location of the prim ers used for reverse tran scription and DNA ampl ification are shown in Figure 1 . Reverse transcription of 1 to 4 J. Lg of total RNA was performed as previously described (10, 24) . Th e products of this reaction were amplified by PCR using Taq polymerase (Perkin Elmer Cetus , Norwalk , CT) and a DNA therm al cycler (Perkin Elmer Cetus). cDNA fragments were pu rified by agarose gel electroelutio n. Conditions for PCR were denatu ring at 94°C for 60 s, an nealing at 52°C for 45 s, and extension at noc for 90 s for a total of 35-40 cycles. For the fragmen t using primers E and F ( Fig. 1) , an annealing temp erature of 45°C was used. Genomic DNA fragments were amplified using the same PCR protocols.
DNA sequencing. Amplified cDNA fragments were subcloned int o a plasmid vecto r (pBluescript; Stratagene, La Jolla, CA) at convenient restric tio n sites. DN A was sequ enced by the dideoxy method (25) using T7 DNA polymerase (Sequenase; US Biochemical, Cleveland, OH ). Nucleotide sequences were analyzed with DNAsis and deduced amino acid sequences with PROsis software (Hitachi America, Brisbane, CA). Compariso n of E1a sequences of both the PDC and the branched-chain keto acid dehydrogenase complex from vario us species was done by searching the National Biomedical Research Foundation data banks usin g the FastA program by the Genetics Com puter Group Analysis Software Package for VAX computers, University of Wiscons in, Madison, WI. The sequence for PDC E ja for nematodes was kindl y provided by Dr. Keith Johnson, University of Toledo, Tole do, OR Dot-blot analysis. Genomi c DN A fragments generated by th e PCR were dot-bl ott ed onto a nylon membrane according to the manufacturer's direction s (Bio-Rad, Richmond, CA). Th e membranes were then hybridized as described (20) with the hybridizatio n mixture contai ning either the T4 polynucleotide kinase radiolabeled wild type or mu tant oligodeoxynucleotide probe ( Fig. I) for several hours at 60T. After hybridization , the membranes were washed at temperatures ranging from 65 to 75T and autoradiographed. RESULT S In previous studies, biochemical and immunologic experiments demonstrated that the proband had variable PD C activity in cells and tissues and that the level of activity corresponded to the amo un t of E] subunit proteins detected by immunoblot analysis (18) . Whereas fibroblasts had normal activity for PD C and its catalytic components, lymphocytes, heart , and liver had minimal PDC and E, activity. Kidney had partial activity for PD C and E j. Th e catalytic activity and immunoreactivity of dihyd rolipoamide acetyltransferase and E 3 components of PDC were normal, and exogenous phospho Ej-phosphatase failed to acti vate PDC activity in tissues with low PDC activity. Th e latter finding indicated th at the lack of E 1 activity was not due to a defect in phospho Ei-phosphatase ( 18) . Sim ilar to a subgroup of pat ients with E, deficiency (4, 6) , th e pro band was missing crossreactive mat erial for both the C(-and the fJ-subunit. To determine whether the defect interfered with tran scription or posttranscriptional processing, RN A blot analysis was perform ed on total RNA isolated from different tissue sources using radiolabeled E,C( and E,fJ cDNA probes (Fig. 2) . The results show that mRNA for E1a and E,fJ were present in liver and heart and were of normal size even th ough these tissues had greatly diminished levels of enzymatic activity. Although the amounts of both EjC( and E1fJ mRNA appear to be greater relative to the control, this is nonspecific becau se the mRNA for E 3 is also increased relative to the control. T here is some varia tio n in the relative intensity of signals for the E,« , E,fJ, and E 3 mRNA between the pati ent and contro l in vario us tissues, but these are qu alitative data obtained from postm ort em sam ples analyzed by seq uential hybrid ization. The relative amounts of E,C(, E1 fJ, and E 3 mRNA were similar in fibroblasts (data not shown). These RNA blot findings, taken as a whole, suggest that the effect of the mutation causing PDC deficiency in this fam ily is posttranscripti onal.
Family studies suggested that the defect might be sex-linked (18) because the proband's brother was affected, the sister and father were normal, and the mother had heterozygote levels of PDC activity. For this reason, the coding region of E1a was sequenced because the gene for this subunit had been localized to the X chro moso me (13 Fig. 2 . RNA blot analysis. Equal amounts of total RNA isolated from liver or heart from the proband (H) and a unrelated hum an control (C) were hybridized with radiolabeled E,IX (left panel) , EII'l (middle panel) , and E 3 (right panel) eDNA fragments. The same mem bran e was used for all of the hybridizations. Th e sizes of E,IX, E,I3, and E 3 are 1.6, 1.5, and 2.2 kb, respectively. Hybridization with E 3 eDNA was used as an internal co ntrol for determin ing the amount of RNA loaded onto the gel. Fig. 3 . DNA sequencing gel. The patient had a point mutation at nucleotide 829 resulting in a guan ine for cytosine substitution . The nucleotide location of the mutation is enclosed in a box. In the normal sequence, there is a doubl et in the cytosine lane, whereas in th e mutant thi s doub let is replaced at a corresponding position by a doublet in the guanine lane . C, cytosine; T, thymidine ; A, adenine; and G, guanine.
PATIENT NORMAL
patient-specific E,(X cDNA fragments from the proband's heart tissue were generated using reverse transcription and PCR amplification. Repeated sequencing of PCR-generated fragments span ning the coding region and flanking 5' and 3' sequences ( Fig. I) indicated that the proband 's E,(X was ident ical to the wild type human E,(X except for a single guanine for cytosine substitution (Fig. 3) at the first nucleotide encoding amino acid 234 of the mature peptide (Fig. 4) . This change causes arginine to be replaced by glycine in exon 8 (II), which contains a stretch of 24 amino acids separatin g phosphorylation sites 3 and I (Fig. 4) .
To ensure that this mutati on was not an artifact of either the reverse transcription or the PCR reaction s, multip le samples of heart RNA were amplified, subcloned, and sequenced. All of these samples were found to have the mutation, whereas concurrent cont rols prepared in the same manner had the wild type sequence. To exclude the possibility that activity in the fibroblasts was due to the presence of a normal allele, E,(X cDNA generated the X chromosome (26) . To avoid the possibility of ampl ifying cDNA from the processed gene, a fragment of genomic DNA from the proband that span ned intron 7 and exon 8 was generated using primers I and G (Fig. I) (11) . The size of the amplified DNA (400 bp) generated was consistent with the fragment being from the E 1a genomic DNA located on the X chromosome. Dotblot analysis of this genom ic DNA fragment using an oligonucleotide containing the mutant sequence (M primer) (Fig. 1) hybridized only with DNA from the two broth ers and mother (data not shown). Comparison of the human E1 a processed gene sequence (26) with the patient-specific cDNA generated from the proband indicated that the latter was from the E1a gene on chromosome X because the codon encoding the arginine residue is CGT for the processed gene (26) in contrast to CGA for the same amino acid on the E1a gene located on the X chromosome (Figs. 4 and 5) . from cultured skin fibroblasts shown previously to have normal activity was also sequenced repeatedly and found to contain only the mutant sequence (Fig. 5B) .
Sequencing of E.a cDNA obtained from cultured skin fibroblasts of other family members (Fig. 5C-F) showed the presence of the mutation in the affected broth er and the mother (Fig. 5C  and D) . However, E,« cDNA from the mother's skin fibroblasts also had the normal sequence (Fig. 5£) , as would be expected for a heterozygous female who carried both the normal and the mutant allele. Because the maternal grandmother had norm al enzymatic activity in lymphocytes (18) , it is probable that the mutation arose in her germ cell line. The father's E1a cDNA (Fig. 5F ) had only the normal sequence.
A processed E 1a gene (intronless) that has been localized to chromosome 4 has a nucleotide sequence that is highly homologous to the E1a cDNA derived from the E1a gene located on
In this report, we have identified a mutation in the coding region of E1a that is associated with variable expression of PDC deficiency. All previously identified mutations affecting E 1 have been located on the a-subunit (14) (15) (16) (17) . Most of these mut ations have been deletions located near the C-terminus of E1a . In the present case, the mutation is located closer to the center of E1a and the reading frame remains intact. There are several lines of evidence indicating that the mutation fou nd in this case accounts for PDC deficiency. First, previous results suggested that the mutation might be located on E1 a because levels of enzymatic activity among family members were consistent with a sex-linked pattern of inheritance (18) . Second , the mutation is most likely located in the coding region of Eja because the defect was associated with normal levels and norm al-sized E.a mRNA. Third, no other mutation was found in the coding region. Fourth, a glycine for arginine substitution is a significant change in both size and charge of an amino acid residue, thereby affecting the secondary structure of E 1 (27, 28) . Th is is especially significant in this case, in which the mutation is located in a critical region (see below). It is unlikely that this mutational change is a protein polymorph ism because such polymorp hisms have not been found in any of the multiple hum an E1a cDNA sequenced by us or other groups (7-10, 14, 15) and this particular residue is highly conserved (see below).
It is surprising that a single point mutation would result in the absence of both the a-and the ,B-subunit in specific tissues, yet 
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173 not affect catalytic activity when both subunits were present. This would suggest that the mutation is in a critical location , which is essential for the stability of the E, heterotetramer. This mutation occurs in exon 8 of Eta , which is situated between phosphorylation site 3 and phosphorylation site I (II ). The identified mutation might alter the secondary structure in this region, thereby affecting the phosphorylation-dephosphorylation of Eta, but this would not account for the lack of immunoreactivity of the two subunits. In additi on, the stretch of amino acids encoded by this exon and the contiguous phosphorylation site I is highly conserved both in length and in am ino acid homology when a comparison is made between the a -subunits from multiple species, both euka ryotic and prokaryotic, of the a -keto acid deh ydrogenase complexes (Fig. 6A) (10, 26, (29) (30) (31) (32) (33) (34) (35) (36) . Th e structure ofthis region is also intere sting. There are multiple nonpolar residues as well as conserved positively and negatively charged am ino acids. Based on Chou-Fasman analy sis (37), there is a strong tend ency for regions within this stretch of amino acids to form a -helical structures. Positively charged amino acids in yeast, nematode, and mammalian Eta tend to be spaced seven or 14 amino acid residues apart (Fig. 6A ) so that these residues would be position ed on the same side of an a-helix. Graphic representation of potential a -helical structures shows that an amphipathic helix (38) is formed , with one side of the helix contammg predominantl y hydrophobic residues and the other side having positively charged residues (Fig. 6B) .
The mutated arginine (amino acid 234) found in this patient is conserved in mammalian Eta including the hum an E1a processed gene and nematode, but not in yeast or other E\a genes from either the PDC or the branched-chain a-keto acid deh ydrogenase complex. However, despite the apparent lack of conservation in the primary structure among the different Eta subunits at this site, the stru cture of a potential a-helix is conserved. For exampl e, all a -keto acid dehydrogenase complexes (except Pseudom onas putida branched-chain keto acid dehydrogenase complex Eta) have a basic am ino acid residue seven amino acids downstream (at position 24 1 of the human sequence) that is not found in mammalian Eta . Thus, the positively charged residue at amino acid 238, which is conserved in all species, is flanked by another positive residue either above or below it in the helical structure so that there are at least two positively charged residues in close proximity on the same side of the helix (Fig. 6B) . It is interesting that the nematode has positive residues at amino acid residues 234 and 24 1 (Fig. 6A) , suggesting that it was at thi s stage of evolutionary developm ent that the hydrophili c residues shifted in position (Fig. 6B ) . In this patient, the substitution of a glycine for arginine would mean the loss of a conserved structural feature found in almost all a-keto acid Eta subunits. Furthermore, glycine could increase the instability of a potential a-helical structure because of enhanced conformational entropy due to the flexibility of this residue (27, 28) .
Based on sequence comparison of the E, subunits of a-keto acid dehydrogenas cs from different species, we have speculated that this region is involved in subunit-subunit interaction because this highly conserved region is found only in a -keto acid dehydrogenas e complexes in which the E t catalytic component has a -and ,B-subunits (39) . Th e interaction between the a-and (3-subunits is kno wn to be ionic (40) , and it has been shown that the presence of both the a -and the ,B-subunit is requi red for protein stability so that when one subunit is missing, the other subunit is also absent (6, 4 1, 42) . Thus, th e presence of a mutation in this region ma y disrupt the ionic interaction between the aand (3-subunits, thereby resulting in the absence of both subunits because a stable heterotetramer cannot form. In this patient, the effect of the mutation may depend on the intracellular environment , thereby causing variable expression of PDC deficiency. Depend ing on intracellular conditions, the substitution of a glycine for arginine may not be sufficient to destabilize the E, heterot etramer. The possibility that intracellular conditions might affect the stability of the E. heterot etramer is suggested by the fact that the a -and ,B-subunit interaction of yeast pyruvate decarboxylase, an enzyme closely related to PDC EI, has been shown to be pH dependent (43) .
There are other possibilities for variable expression of PDC deficiency in this patient. A glycine in place of arginine might make Eta more susceptible to sequence-specific proteases, which may be present in certain tissues (27) . Tissue variable expression has also been described in cytochrome oxidase deficiency (44, 45) , and the explan ation in those cases was isozymic variation. In the case of Eta , there is no evidence of isozymes except for the processed E1 a gene on chromosome 4 (26) . It may be possible that in our patient this gene was both transcribed and transl ated in cultured skin fibroblasts and that this gene produ ct replaced the mu tant Eta , thereby restoring activity. Ho wever, Dahl et al. (26) ha ve shown th at this gene is only transcribed in postm eiotic sperm atogenic cells. Another possibility is that there was allelic variation in different tissues of the patient due to mosaicism of the X chromosome such that tissues with normal activity had a normal E1a gene. Similar mosaicism has been described with other X-linked disorders such as ornithine transcarbamylase deficiency (46) . However, this app ears unlikely in this case because only the mutant allele was identified in cultured skin fibroblasts with normal activity. Further investigation will be required to determine the intracellular factors responsible for tissue variable PDC deficiency. Expression of the mutant phenotype would ordinarily be useful in determining the significance of this mutation in causing variable PDC deficiency. However, introduction of this mutation into Ej-deficient cultured fibroblasts by transfection would in all likelihood restore normal activity because this mutation is not expressed in the patient's cultured fibroblasts. Therefore, it will be necessary to establish an Er-deficient animal model and introduce a transgene carrying the mutant E1a into the animal's genome. It would then be possible to determine the specific factors responsible for variable PDC deficiency.
